In summary, we have identified the PARG inhibitor ethacridine as a novel combination candidate for erlotinib in AML. Erlotinib synergizes with ethacridine by potentiating its intracellular accumulation; however, the mechanism by which ethacridine accumulates in TEX and OCI-AML2 cells remains to be elucidated. The potential impact of PARG inhibition as a therapeutic strategy in AML warrants further investigation.
Erlotinib synergizes with the poly (ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells
DATTI, AlessandroSupervision
;
2016
Abstract
In summary, we have identified the PARG inhibitor ethacridine as a novel combination candidate for erlotinib in AML. Erlotinib synergizes with ethacridine by potentiating its intracellular accumulation; however, the mechanism by which ethacridine accumulates in TEX and OCI-AML2 cells remains to be elucidated. The potential impact of PARG inhibition as a therapeutic strategy in AML warrants further investigation.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
